Intra-Cellular ups sales guidance

 Q2 2023 total revenues increased to $110.8 million, compared to $55.6 million in the same period in 2022

CAPLYTA Q2 2023 net product sales were $110.1 million, compared to $55.1 million for the same period in 2022, representing a 100% increase

CAPLYTA’s strong prescription uptake continues: Q2 2023 CAPLYTA total prescriptions increased 96%, versus the same period in 2022 and 13% sequentially versus Q1 2023

2023 CAPLYTA net product sales guidance raised to $445 - $465 million

https://www.biospace.com/article/releases/intra-cellular-therapies-reports-second-quarter-2023-financial-results-and-raises-2023-caplyta-sales-guidance-/